Professor BENJAMIN OLLIVERE's Outputs (3)

HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19 (2022)
Journal Article
Astbury, S., Reynolds, C. J., Butler, D. K., Munoz-Sandoval, D. C., Lin, K.-M., Pieper, F. P., Otter, A., Kouraki, A., Cusin, L., Nightingale, J., Vijay, A., Craxford, S., Aithal, G. P., Tighe, P. J., Gibbons, J. M., Pade, C., Joy, G., Maini, M., Chain, B., Semper, A., …Altmann, D. M. (2022). HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19. Immunology, 166(1), 68-77. https://doi.org/10.1111/imm.13450

SARS-CoV-2 infection results in different outcomes ranging from asymptomatic infection to mild or severe disease and death. Reasons for this diversity of outcome include differences in challenge dose, age, gender, comorbidity and host genomic variati... Read More about HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19.

Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection (2021)
Journal Article
Urbanowicz, R. A., Tsoleridis, T., Jackson, H. J., Cusin, L., Duncan, J. D., Chappell, J. G., Tarr, A. W., Nightingale, J., Norrish, A. R., Ikram, A., Marson, B., Craxford, S. J., Kelly, A., Aithal, G. P., Vijay, A., Tighe, P. J., Ball, J. K., Valdes, A. M., & Ollivere, B. J. (2021). Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Science Translational Medicine, 13(609), Article eabj0847. https://doi.org/10.1126/scitranslmed.abj0847

Understanding the impact of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the response to vaccination is a priority for responding to the coronavirus disease 2019 (COVID-19) pandemic. In particular, it is necess... Read More about Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection.

Serum glucose, lactate dehydrogenase and hypertension are mediators of the 1 effect of body mass index on severity of COVID-19 (2021)
Journal Article
Yan, H., Vijay, A., Jiang, F., Zheng, N., Hu, Y., Ye, H., Ollivere, B., Cai, T., Valdes, A. M., & Aithal, G. P. (2021). Serum glucose, lactate dehydrogenase and hypertension are mediators of the 1 effect of body mass index on severity of COVID-19. Endocrinology, Diabetes and Metabolism, 4(2), Article e00215. https://doi.org/10.1002/edm2.215

Background: COVID-19 has a broad clinical specturm. We investigated the role of serum markers measured on admission on severity as assessed at discharge and investigated those which relate to the effect of BMI on severity.
Methods: Clinical and la... Read More about Serum glucose, lactate dehydrogenase and hypertension are mediators of the 1 effect of body mass index on severity of COVID-19.